2-MeOE2bisMATE induces caspase-dependent apoptosis in CAL51 breast cancer cells and overcomes resistance to TRAIL via cooperative activation of caspases

Apoptosis

Volumn 9, Issue 3, 2004, Pages 323-332

  Wood, L ^a   Leese, M P ^b   Mouzakiti, A ^a   Purohit, A ^c   Potter, B V L ^b   Reed, M J ^c   Packham, G ^a,d  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^b University of Bath   (United Kingdom)

^c ST MARY S HOSPITAL   (United Kingdom)

^d SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

Author keywords

2 Methoxyoestradiol; Caspase; Death receptor; Oestrogen

Indexed keywords

2 METHOXYESTRADIOL; BENZYLOXYCARBONYLVALYLALANYLASPARTYL FLUOROMETHYL KETONE; CASPASE; CASPASE 3; CASPASE 8; CASPASE 9; FAS ANTIGEN; PROTEIN BID; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

APOPTOSIS; ARTICLE; BREAST CARCINOMA; CANCER CELL CULTURE; CELL DEATH; CELL KILLING; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME ACTIVATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; BIOLOGICAL AVAILABILITY; BREAST NEOPLASMS; CASPASES; CELL LINE, TUMOR; CELL SURVIVAL; ENZYME ACTIVATION; EPITHELIAL CELLS; ESTRADIOL; HUMANS; MEMBRANE GLYCOPROTEINS; MOLECULAR STRUCTURE; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR NECROSIS FACTOR-ALPHA;

EID: 3242808959     PISSN: 13608185     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:APPT.0000025809.80684.bd     Document Type: Article

References (56)

1. Stennicke HR, Salvesen GS. Caspases - Controlling intracellular signals by protease zymogen activation. Biochim Biophys Acta 2000; 1477: 299-306.
2. Kroemer G. Mitochondnal control of apoptosis: An introduction. Biochem Biophys Res Commun 2003; 304: 433-435.
3. Tsujimoto Y. Cell death regulation by the Bcl-2 protein family in the mitochondria. Journal of Cell Physiol 2003; 195: 158-167.
4. Ashkenazi A, Dixit VM. Death receptors: Signaling and modulation. Science 1998; 281: 1305-1308.
5. Luo X, Budihardjo I, Zou H, Slaughter C, Wang X. Bid, a Bcl-2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors. Cell 1998; 94: 481-490.
6. Li H, Zhu H, Xu CJ, Yuan J. Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell 1998; 94: 491-501.
7. D'Amato RJ, Lin CM, Flynn E, Folman J, Hamel E. 2-Methoxyestradiol, an endogenous mammalian metabolite, inhibits tubulin polymerization by interacting at the colchicine site. Proc Natl. Acad Sci USA 1994; 91: 3964-3968.
8. Sattler M, Quinnan LR, Pride YB, et al. 2-Methoxyestradiol alters cell motility, migration, and adhesion. Blood 2003; 102: 289-296.
9. Yue TL, Wang X, Louden CS, et al. 2-Methoxyestradiol, an endogenous estrogen metabolite, induces apoptosis in endothelial cells and inhibits angiogenesis: Possible role for stress-activated protein kinase signaling pathway and Fas expression. Mol Pharmacol 1997; 51: 951-962.
10. Reiser F, Way D, Bernas M, Witte M, Witte C. Inhibition of normal and experimental angiotumour endothelial cell proliferation and cell cyle progression by 2-methoxyestradiol. Proc Soc Exp Biol Med 1998; 219: 211-216.
11. Chauhan D, Catley L, Hideshima T, et al. 2-Methoxyestradiol overcomes drug resistance in multiple myeolma cells. Blood 2002; 100: 2187-2194.
12. MacCarthy-Morrogh L, Townsend PA, Purohit A, et al. G. Differential effects of estrone and estrone-3-O-sulfamate derivatives on mitotic arrest, apoptosis, and microtubule assembly in human breast cancer cells. Cancer Res 2000; 60: 5441-5450.
13. Mabjeesh NJ, Escuin D, La Vallee TM, et al. 2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF. Cancer Cell 2003; 3: 363-375.
14. Fotsis T, Zhang Y, Pepper MS, et al. The endogenous oestrogen metabolite 2-methoxyoestradiol inhibits angiogenesis and suppresses tumour growth. Nature 1994; 368: 237-239.
15. Klauber N, Parangi S, Flynn E, Hamel E, D'Amato RJ. Inhibition of angiogenesis and breast cancer in mice by the microtubule inhibitors 2-methoxyestradiol and taxol. Cancer Res 1997; 57: 81-86.
16. Yue TL, Wang X, Louden CS, et al. 2-Methoxyestradiol, an endogenous estrogen metabolite, induces apoptosis in endothehal cells and inhibits angiogenesis: Possible role for stress-activated protein kinase signalling pathway and Fas expression. Mol Pharmacol 1997; 51: 951-962.
17. LaVallee TM, Zhan XH, Herbstritt CJ, Kough EC, Green SJ, Pribluda VS. 2-Methoxyestradiol inhibits proliferation and induces apoptosis independantly of estrogen receptors alpha and beta. Cancer Res 2002; 62: 3691-3697.
18. Mukhopadhyay T, Roth JA. Induction of apoptosis in human lung cancer cells after wild-type p53 activation by methoxyestradiol. Oncogene 1997; 14: 379-384.
19. Seegers JC, Lottering ML, Grobler CJ, et al. The mammalian metabolite, 2-methoxyestradiol, affects P53 levels and apoptosis induction in transformed cells but not in normal cells. J Steroid Biochem Mol Biol 1997; 62: 253-267.
20. Carothers AM, Hughes SA, Ortega D, Bertagnolli MM. 2-Methoxyestradiol induces p53-associated apoptosis of colorectal cancer cells. Cancer Lett 2002; 187: 77-86.
21. Vousden KH, Lu X. Live or let die: The cell's response to p53. Nat Rev Cancer 2002; 2: 594-604.
22. Attalla H, Westberg JA, Andersson LC, Adlercreutz H, Makela TP. 2-Methoxyestradiol-induced phosphorylation of Bcl-2: Uncoupling from JNK/SAPK activation. Biochem Biophys Res Commun 1998; 247: 616-619.
23. Basu A, Haldar S. Identification of a novel Bcl-xL phosphorylation site regulating the sensitivity of taxol- or 2-methoxyestradiol-induced apoptosis. FEBS Lett 2003; 538: 41-47.
24. Kumar AP, Garcia GE, Orsborn J, Levin VA, Slaga TJ. 2-Methoxyestradiol interferes with NF kappa B transcriptional activity in primitive neuroectodermal brain tumours: Implications for management. Carcinogenesis 2003; 24: 209-216.
25. Lee HH, Dadgostar H, Cheng Q, Shu J, Cheng G. NF-kappaB-mediated up-regulation of Bcl-x and Bfl-1/A1 is required for CD40 survival signalling in B lymphocytes. Proc Natl Acad Sci USA 1999; 96: 9136-9141.
26. Zong WX, Edelstein LC, Chen C, Bash J, Gelinas C. The prosurvival Bcl-2 homolog Bfl-1/A1 is a direct transcriptional target of NF-kappaB that blocks TNFalpha-induced apoptosis. Genes Dev 1999; 13: 382-387.
27. Huang P, Feng L, Oldham EA, Keating MJ, Plunkett W. Superoxide dismutase as a target for the selective killing of cancer cells. Nature 2000; 407: 390-395.
28. Zhou Y, Hileman EO, Plunkett W, Keating MJ, Huang P. Free radical stress in chronic lymphocytic leukaemia cells and its role in cellular sensitivity to ROS-generating anticancer agents. Blood 2003; 101: 4098-4104.
29. Kachadourian R, Liochev SI, Cabelli D, Patel MN, Fridovich I, Day BJ. 2-Methoxyestradiol does not inhibit superoxide dismutase. Arch Biochem Biophys 2001; 392: 349-353.
30. LaVallee TM, Zhan XH, Johnson MS, et al. 2-Methoxyestradiol up-regulates death receptor 5 and induces apoptosis through activation of the extrinsic pathway. Cancer Res 2003; 63: 468-475.
31. Purohit A, Hejaz HA, Walden L, et al. The effect of 2-methoxyoestrone-3- O-sulphamate on the growth of breast cancer cells and induced mammary tumours. Int J Cancer 2000; 85: 584-589.
32. Day JM, Newman SP, Comninos A, et al. The effects of 2-substituted oestrogen sulphamates on the growth of prostate and ovarian cancer cells. J Steroid Biochem Mol Biol 2003; 84: 317-325.
33. Wood L, Leese MP, Leblond B, et al. Inhibition of superoxide dismutase by 2-methoxyoestradiol analogues and oestrogen derivatives: Structure-activity relationships. Anticancer Drug Design 2001; 16: 209-215.
34. Raobaikady B, Purohit A, Chander SK, et al. Inhibition of MCF-7 breast cancer cell proliferation and in vivo steroid sulphatase activity by 2-methoxyoestradiol-bis-sulphamate. J Steroid Biochem Mol Biol 2003; 84: 351-358.
35. Newman SP, Leese MP, Purohit A, James DR, Rennie CE, Potter BV, Reed MJ. Inhibition of in vitro angiogenesis by 2-methoxy and 2-ethyl-estrogen sulfamates. Int J Cancer 2004; 109(4): 533-540. PMID: 14991574 [pubmed-in process].
36. Suzuki RN, Newman SP, Purohit A, et al. Growth inhibition of multi-drug-resistant breast cancer cells by 2-methoxyoestradiol-bis-sulphamate and 2-ethyloestradiol-bis-sulphamate. Journal of Steroid Biochemistry & Molecular Biology 2003; 84: 269-278.
37. Ireson CR, Chander SK, Purohit A, Perena S, Newman SP, Parish D, Leese MP, Smith AC, Potter BV, Reed MJ. Pharamacokinetics and efficacy of 2-methoxyoestradiol and 2-methoxyoestradiol sulphamate in vivo in rodents. Br J Cancer, 2004; 90(4): 932-937. PMID: 14970876 [pubmed-in process].
38. Gioanni J, Le Francois D, Zanghellini E, et al. Establishment and characterisation of a new tumorigenic cell line with a normal karyotype derived from a human breast adenocarcinoma. Br J Cancer 1990; 62: 8-13.
39. Brimmell M, Burns JS, Munson P, et al. High level expression of differentially localized BAG-1 isoforms in some oestrogen receptor-positive human breast cancers. Br J Cancer 1999; 81: 1042-1051.
40. Ariumi Y, Ueda K, Masutani M, et al. In vivo phosphorylation of poly (ADP-ribose) polymerase is independent of its activation. FEBS Letters 1998; 436: 288-292.
41. Germain M, Affar EB, D'Amours D, Dixit VM, Salvesen GS, Poirier GC. Journal of Biological Chemistry 1999; 274: 28379-28384.
42. Mouzakiti A, Packham G. Regulation of tumour necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in Burkitt's lymphoma cell lines. Br J Haematol 2003; 122: 61-69.
43. Schotte P, Declercq W, Van Huffel S, Vandenabeele P, Beyaert R. Non-specific effects of methyl ketone peptide inhibitors of caspases. FEBS Letters 1999; 442: 117-121.
44. Yamamoto K, Ichijo H, Korsmeyer SJ. BCL-2 is phosphorylated and inactivated by an ASK1/Jun N-terminal protein kinase pathway normally activated at G(2)/M. Mol Cell Biol 1999; 19: 8469-8478.
45. Chauhan D, Catley L, Hideshima T, et al. 2-Methoxyestradiol overcomes drug resistance in multiple myeloma cells. Blood 2002; 100: 2187-2194.
46. Newton K, Harris AW, Bath ML, Smith KG, Strasser A. A dominant interfering mutant of FADD/MORT1 enhances deletion of autoreactive thymocytes and inhibits proliferation of mature T lymphocytes. EMBO J 1998; 17: 706-718.
47. Hua ZC, Sohn SJ, Kang C, Cado D, Winoto A. A function of fas-associated death domain protein in cell cycle progression localized to a single amino acid and its C-terminal region. Immunity 2003; 18: 513-521.
48. Walsh CM, Wen BG, Chainnaiyan AM, O'Rourke K, Dixit VM, Hedrick SM. A role for FADD in T cell activation and development. Immunity 1998; 8: 439-449.
49. Zornig M, Hueber AO, Evan G. p53-dependent impairment of T-cell proliferation in FADD dominant-negative transgenic mice. Curr Biol 1998; 8: 467-470.
50. Scaffidi C, Volkland J, Blomberg I, Hoffmann I, Krammer PH, Peter ME. Phosphorylation of FADD/MORT1 at serine 194 and association with a 70-kDa cell cycle-regulated protein kinase. J Immunology 2000; 164: 1236-1242.
51. Ashkenazi A, Pai RC, Fong S, et al. Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 1999; 104: 155-162.
52. Walczak H, Miller RE, Ariail K, et al. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med 1999; 5: 157-163.
53. Lacour S, Micheau O, Hammann A, et al. Chemotherapy enhances TNF-related apoptosis-inducing ligand DISC assembly in HT29 human colon cancer cells. Oncogene 2003; 22: 1807-1816.
54. Ohtsuka T, Buchsbaum D, Oliver P, Makhija S, Kimberly R, Zhou T. Synergistic induction of tumor cell apoptosis by death receptor antibody and chemotherapy agent through JNK/p38 and mitochondrial death pathway. Oncogene 2003; 22: 2034-2044.
55. Bu S, Blaukat A, Fu X, Heldin NE, Landstrom M. Mechanisms for 2-methoxyestradiol-induced apoptosis of prostate cancer cells. FEBS Lett 2002; 531: 141-151.
56. Djavaheri-Mergny M, Wietzerbin J, Besancon F. 2-Methoxyestradiol induces apoptosis in Ewing sarcoma cells through mitochondrial hydrogen peroxide production. Oncogene 2003; 22: 2558-2567.